Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Johnson & Johnson Diabetes Drug Endorsed by Review Panel


A panel of FDA advisers recommended the drug Invokana be approved for sale. But concerns over heart attack, stroke, and other cardiovascular risks linger.

A panel of government advisers recommended on a 10-5 vote Thursday that Johnson & Johnson's (NYSE:JNJ) experimental diabetes drug Invokana should be approved by the Food and Drug Administration.

The vote is a win for J&J as it hopes to get clearance for its first prescription drug for diabetes. The company conducted a massive study of more than 10,000 people to show the benefits of the medicine. On a separate vote, the panelists were split, 8-7, on whether the company provided evidence that Invokana's risk of heart attack, stroke and other cardiovascular events is acceptable under FDA guidelines.

Invokana controls blood sugar levels and is part of a new class of drugs. Eli Lilly (NYSE:LLY) and partner Boehringer Ingelheim also hope to win approval for a similar drug. Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca (NYSE:AZN) recently won European approval for their drug after the FDA shot it down early last year. The FDA is expected to rule on the J&J drug by late March.

(See Johnson & Johnson Diabetes Medicine Faces Big Test.)

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos